- Home
- GCMG vs RAPT Comparison
GCMG vs RAPT Comparison
Compare GCMG & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- RAPT
- Stock Information
- Founded
- GCMG 1971
- RAPT 2015
- Country
- GCMG United States
- RAPT United States
- Employees
- GCMG N/A
- RAPT N/A
- Industry
- GCMG Finance/Investors Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- RAPT Health Care
- Exchange
- GCMG Nasdaq
- RAPT Nasdaq
- Market Cap
- GCMG 611.5M
- RAPT 498.4M
- IPO Year
- GCMG N/A
- RAPT 2019
- Fundamental
- Price
- GCMG $11.26
- RAPT $28.55
- Analyst Decision
- GCMG Buy
- RAPT Strong Buy
- Analyst Count
- GCMG 4
- RAPT 9
- Target Price
- GCMG $14.88
- RAPT $57.00
- AVG Volume (30 Days)
- GCMG 837.5K
- RAPT 584.7K
- Earning Date
- GCMG 11-05-2025
- RAPT 11-06-2025
- Dividend Yield
- GCMG 4.29%
- RAPT N/A
- EPS Growth
- GCMG N/A
- RAPT N/A
- EPS
- GCMG 0.32
- RAPT N/A
- Revenue
- GCMG $543,085,000.00
- RAPT N/A
- Revenue This Year
- GCMG $4.88
- RAPT N/A
- Revenue Next Year
- GCMG $11.59
- RAPT N/A
- P/E Ratio
- GCMG $34.93
- RAPT N/A
- Revenue Growth
- GCMG 17.40
- RAPT N/A
- 52 Week Low
- GCMG $11.19
- RAPT $5.67
- 52 Week High
- GCMG $14.48
- RAPT $42.39
- Technical
- Relative Strength Index (RSI)
- GCMG 28.78
- RAPT 52.45
- Support Level
- GCMG $11.55
- RAPT $26.78
- Resistance Level
- GCMG $11.73
- RAPT $29.90
- Average True Range (ATR)
- GCMG 0.11
- RAPT 1.64
- MACD
- GCMG 0.00
- RAPT -0.43
- Stochastic Oscillator
- GCMG 11.11
- RAPT 38.42
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.